Morphosys Ag

Trigen Gmbh

Galapagos Nv

Mor0059us.np

Corimmun Gmbh

Helmhotz Zentrum Munchen, Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (gmbh)

Advancecor Gmbh

Andreas Bültmann

Götz Münch

Meinrad Gawaz

Josef Prassler

Markus Moosmeier

Roger Müller

Steffen Massberg

Martin Ungerer

Mario Peluso

Reginald Christophe Xavier Brys

Julia Neugebauer

Thomas Tiller

Elisabeth Kremmer

Steffen Runz

Luc Nelles

Katja Conrath

Robert Mühlbacher

Teresa Garcia

Götz MÜNCH

Roger MÜLLER

The present disclosure provides humanized antibodies that specifically bind to CD3 with an optimized affinity and induce T cell-mediated killing of tumour related target antigen high expressing cells with high potency but have limited killing activity on target antigen low expressing cells. The present disclosure also provides bispecific antibodies comprising a first antigen-binding domain that specifically binds to human CD3 with optimized affinity and a second antigen-binding molecule that specifically binds a tumor-related antigen. The disclosure further relates to methods of generating such humanized antibodies and bispecific antibodies for biological, diagnostic, pharmaceutical and other uses.

Humanized antibodies for CD3

The invention relates to novel polypeptide libraries that are conformationally constrained in an anti-parallel, helix-turn-helix arrangement. The invention further relates to methods of generating and screening such libraries for biological, pharmaceutical and other uses.

Polypeptide library

The present invention provides antagonists of IL17C for use in the treatment of an inflammatory disorder.

Antagonists of IL17C for the treatment of inflammatory disorders

The present invention provides anti-thrombotic agents, methods for screening for said anti-thrombotics agents and methods of treating thrombotic and other cardiovascular disorders.

Antibodies which bind to epitopes of glycoprotein VI

The present invention provides a fusion protein comprising (1) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and (b) the Fc domain of the immunoglobulin or a function-conservative part thereof, characterized by a polypeptide chain having an amino acid sequence as shown in FIG.and whereby the fusion protein is obtainable by a process which provides the fusion protein in the form of a specific dimer.

Immunoadhesin comprising a glycoprotein VI domain

The present invention provides a fusion protein comprising (a) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and (b) the Fc domain of an immunoglobulin or a function-conservative part thereof, characterised by a polypeptide chain having an amino acid sequence as shown in FIG.and whereby the fusion protein is obtainable by a process which provides the fusion protein in the form of a specific dimer.

Polynucleotides encoding immunoadhesins comprising a glycoprotein VI domain

Growing community of inventors

Planegg, Germany

Andreas Bültmann